MS Academy 2021

Hot topics that matter today: Clinical vulnerability and vaccination

The MS Academy is a medical education initiative by Bayer. In previous years, it consisted of a yearly educational event. Due to the restrictions associated with the COVID-19 pandemic the program goes virtual and will consist of three webinars each of one hour of duration and taking place in September, October and November. The 2021 program of the MS Academy focusses on the current hot topics of clinical vulnerability and vaccination in multiple sclerosis (MS). During the first webinar the special needs of the ageing MS population will be discussed. In the second webinar pathomechanisms and available data on infections in MS patients will be reviewed from the neurology and from the infectiology viewpoint, followed by a lessons learned for clinical practice session. The last webinar shall be fully dedicated to the topic of vaccination, particularly to the new joint ECTRIMS/EAN vaccination recommendations, which are anticipated to come out in October 2021.

Die Informationen auf den nächsten Seiten dürfen nur medizinischen Fachkreisen zugänglich gemacht werden (Heilmittelwerbegesetz). Sie haben die Möglichkeit sich sowohl über den Bayer Vital Login als auch über DocCheck einzuloggen.

Sollten Sie noch bei keinem dieser Services registriert sein, melden Sie sich bitte dort an. Es warten noch viele weitere interessante Artikel und Services auf Sie.

September 7, 18 – 19h CET

Speaker’s bureau:

  • Mar Tintore, CEMCAT, University Hospital Vall d'Hebron, Barcelona, Spain, Chairperson
  • Jennifer Graves, University of California San Diego Health, San Diego, CA, USA
  • Sven Meuth, University Hospital Düsseldorf, Düsseldorf, Germany

 

Agenda:

18.00 – 18.05

Welcome and introduction

Mar Tintore

18.05 – 18.30

MS in the ageing population: (Neuro)immunological aspects

(includes short presentation, interactive elements and Q&A)

Sven Meuth

18.30 – 18.55

MS in the ageing population: Current data and lessons for clinical practice

(includes short presentation, interactive elements and Q&A)

Jennifer Graves

18.55 – 19.00

Closing remarks

Mar Tintore

 

Short description:

Over half of the patients with MS in western countries are now 45 years of age or older; a general trend towards increased longevity in patients with MS is noticed (1-4). Beyond the visible signs of ageing, becoming older also means a higher likelihood of immunosenescence, inflamm-ageing, co-morbidities, and less biological reserve. Not everyone ages equally quickly and chronological and biological age may differ. Patients with MS seem to be susceptible to accelerated biological ageing and may therefore be ‘older’ than their years (5), at the same time as age affects MS (1). These issues as well as the interplay with co-morbidities have so far received relatively little attention. The objective of this webinar is to shed light on those topics and to discuss how to better consider the special needs of older patients with MS or of those with comorbidities, in order to ultimately improve the management of the ageing population with MS.

  1. Vaughn CB et al. Nat Rev Neurol 2019; 15(6): 329-42.
  2. Daltrozzo T et al. Front Neurol 2018; 9: 871.
  3. UK Government. MS data briefing, February 2020. Available at: https://www.gov.uk/government/publications/multiple-sclerosis-prevalence-incidence-and-smoking-status/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing
  4. Wallin MT et al. Neurology 2019; 92(10): e1029-40.
  5. Mills EA, Mao-Draayer Y. Mult Scler 2018; 24(8): 1014-22.

für das Web-Seminar am 07.09.2021:

October 27, 18 – 19h CET

Speaker’s bureau:

  • Mar Tintore, CEMCAT, University Hospital Vall d'Hebron, Barcelona, Spain, Chairperson
  • Anthony Reder, University of Chicago, Chicago, USA 
  • Isabel Ruiz, CEMCAT, University Hospital Vall d'Hebron, Barcelona, Spain

 

Agenda:

18.00 – 18.05

Welcome and introduction

Mar Tintore

18.05 – 18.30

Infections in patients with MS

  • Neurology viewpoint: Frequency and clinical data
  • Infectiology viewpoint: Frequent infections and pathomechanisms

 (includes short presentation, interactive elements and Q&A)

 

Anthony Reder

Isabel Ruiz

 

18.30 – 18.55

Clinical management

  • Infectiological considerations
  • Neurological considerations

 (includes short presentation, interactive elements and Q&A)

 

Isabel Ruiz

Anthony Reder

 

18.55 – 19.00

Closing remarks

Mar Tintore

 

Short description:

MS patients have an increased risk of infections compared to the general population. Several factors influence the risk of infections in patients with MS such as the patient’s disability severity, the patient’s age, the treatment he/she is taking or the patient’s overall health. This session is a deep dive into MS and infections and on what makes MS patients more vulnerable to infections: Pathomechanisms, frequency, available data, influence of therapy and lessons learned for clinical management will be reviewed from the neurology and infectiology viewpoint.

November 16, 18 – 19h CET

Speaker’s bureau:

  • Mar Tintore, CEMCAT, University Hospital Vall d'Hebron, Barcelona, Spain, Chairperson
  • Susana Otero, Department of Preventive Medicine and Epidemiology, University Hospital Vall d'Hebron, Barcelona, Spain 
  • Massimo Filippi, Neurology Unit, MS Center, IRCCS San Raffaele Scientific Institute, Milan, Italy

 

Agenda:

18.00 – 18.05

Welcome and introduction

Mar Tintore

18.05 – 18.20

Insights into the new recommendations

Susana Otero

18.20 – 18.30

COVID vaccination in MS: Experience and aspects to consider

Massimo Filippi

18.30 – 18.55

Interactive panel discussion

 

18.55 – 19.00

Closing remarks

Mar Tintore

 

Short description:

The subject of vaccination is scientifically complex and the complexity increases when the patient suffers from a chronic disease like MS and takes a medication which interacts with immune mechanisms. As a clinician you are challenged to have well-founded answers to your patients' questions. At least in some countries, national guidelines have been developed which provide important guidance on the subject. Now the joint ECTRIMS/EAN initiative is making efforts to establish international vaccination recommendations. The guidelines are anticipated for ECTRIMS 2021. The webinar will provide you with insights into these new recommendations and – out of actuality – discuss aspects related to COVID 19 vaccination and MS. Furthermore, it allows you to discuss clinical questions around MS and vaccination with experts from the initiative. Please send your questions in advance of the webinar to EMAIL.


MS Academy Berlin

21.-23. Februar 2020

The Multiple Sclerosis Academy is an educational workshop on MS management and visit of clinic for Neurology, Charité, Berlin, Germany, a German Clinical Center of Excellence for MS management

Aufzeichnungen

Dr. Nadja Siebert, Charité Berlin

MS, treatment and pregnancy

PP-BET-DE-0314-1

Susanna Asseyer, Charité Berlin

The aging MS-Patient - comorbidities and aspects of immunosenescence

PP-BET-DE-0326-1

Dr. Christian Veauthier, Charité Berlin

MS and sleep

Dr. Anja Mähler, Charité, Berlin

Lifestyle and diet – influence on MS outcomes

 

Dr. Magd Zakaria, Ain Shams University, Cairo

Is it still appropriate to prescribe interferon beta for newly diagnosed active MS?

PP-BET-DE-0315-1